Profound Medical CEO Arun Menawat To Become Executive Chair In January, And The Company Retires Its Index 20 Gauge
President Richard Fabian takes over as chief executive on January 14, 2027, as Profound drops the utilization gauge it had shown investors.
Profound Medical, which makes MRI-guided devices that destroy diseased tissue without incisions, said on its third-quarter earnings call Thursday that President Richard Fabian will succeed Chairman and CEO Arun Menawat on January 14, 2027. The company has also retired Index 20, the program it used to show how heavily its Tulsa systems were being used.
Menawat steps up to executive chair
Dr. Arun Menawat, the company's chief executive and chairman, said he will move to executive chair, working with Fabian on strategy and investor relations. He noted the change coincides with his 72nd birthday, adding that he still has "a strong passion to see this all the way."
Menawat also said Mathieu Sobczyk is now permanent chief financial officer, and that Jason Mills is joining the board, succeeding Cynthia Lavoie. Future analyst calls will be led by Fabian, Menawat said.
Fabian listed three priorities: turning the sales pipeline into placed systems, helping customers raise utilization, and improving operating efficiency as the company scales.
Index 20 is gone
Asked by an analyst from Lake Street where the Index 20 metric had gone, Menawat answered: "We retired that program." With 98 sites installed, he said, the gauge "was kind of losing its original purpose," and he expects the count to be well over 100 before year-end.
Pressed by Blake Fomi of Cougar Capital on how utilization would be reported, Fabian said the next step is to see what the reporting cadence looks like and "be transparent with our investment community." Menawat said Fabian will develop a new metric.
On utilization itself, Menawat described year-over-year growth as "in that mid-double digit range," the same as last year. He said the hurdles are logistics and workflow, not clinical data or reimbursement. Chief Commercial Officer Tom Tamberrino said the company is "still relatively light" on revenue from procedural growth and will add program development managers whose job is to drive procedure volume.
Quarter and outlook
Third-quarter revenue was $9.8 million, up 86% from a year earlier, Sobczyk said. That included $4.1 million of recurring revenue and $5.7 million of capital equipment sales. Gross margin was 78%, against 74% a year earlier.
The net loss narrowed 3% to about $7.7 million, or 21 cents a share. Operating cash use was $5 million, down from $11.3 million in the second quarter. Cash stood at about $33.3 million at the end of September.
The company projects 2026 revenue of at least $25 million and gross margin of 70% or higher. Tamberrino said the qualified sales pipeline for Tulsa Pro and Sana Leaf was about $79.2 million, predominantly capital equipment with a little consumables revenue.
Menawat said the one-year CAPTAIN trial data, including recurrence and side effects, is targeted for RSNA in early December, and 2027 growth targets will be detailed early next year.
Sources
- Profound Medical (PROF) Reports Q3 Loss, Beats Revenue Estimates — Yahoo Finance
- Profound Medical Q3 2026 Earnings Call Transcript — benzinga.com
- Profound Medical (PROF) Expected to Beat Earnings Estimates: Should You Buy? — Yahoo Finance
- Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates — Yahoo Finance
- Profound Medical Corp. Form 8-K filed November 3, 2026 — sec.gov